Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in Gastroenterology and Hepatology
This week's episode covers new sedation guidelines for endoscopy, advances in HCC and NET treatments, GLP-1 agonists for MASH, and innovative approaches in cancer research including organoids and photomedicine.
Bibliography
1. Sedation for gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) Guideline.
Authors: Triantafyllou K, Tziatzios G, Tham TC, et al.
Journal: Endoscopy, 2026 Oct
PMID: 42480549
DOI: 10.1055/a-2898-6540
2. Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma.
Authors: Tran NH, Palmer ME, Ulrich A, et al.
Journal: The oncologist, 2026 Sep 9
PMID: 42640574
DOI: 10.1093/oncolo/oyag343
3. Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
Authors: Yen CJ, Chen MH, Chen YY, et al.
Journal: British journal of cancer, 2026 Oct
PMID: 42393461
DOI: 10.1038/s41416-026-03515-w
4. Targeting the CD31 immunometabolic axis: Precision strategies for modulating T cell activation, migration, and autophagy.
Authors: Han X, Yang F, Huang C, et al.
Journal: Pathology, research and practice, 2026 Oct
PMID: 42492206
DOI: 10.1016/j.prp.2026.156629
5. MicroRNA-122 as a regulator and biomarker of liver disease.
Authors: Ahmadova S, Wicik Z, Mucha J, et al.
Journal: Journal of molecular medicine (Berlin, Germany), 2026 Sep 19
PMID: 42760391
DOI: 10.1007/s00109-026-02718-1
6. Colorectal cancer organoid co-culture systems and their applications in drug screening.
Authors: Xu Y, Xing T, Zhang S, et al.
Journal: Chemico-biological interactions, 2026 Oct 1
PMID: 42551539
DOI: 10.1016/j.cbi.2026.112277
7. Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.
Authors: Tavaglione F, Loomba R
Journal: Cell reports. Medicine, 2026 Sep 15
PMID: 42697203
DOI: 10.1016/j.xcrm.2026.103023
8. The circadian-melatonin axis in breast cancer metastasis: molecular mechanisms, organ-specific metastatic niches, and therapeutic opportunities.
Authors: Wang CH, Chong KH, Cheng CF, et al.
Journal: Frontiers in endocrinology, 2026
PMID: 42755785
DOI: 10.3389/fendo.2026.1941609
9. Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy.
Authors: Russano F, Dall'Olmo L, Brugnolo D, et al.
Journal: International journal of molecular sciences, 2026 Sep 13
PMID: 42794589
DOI: 10.3390/ijms27188156
10. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Authors: Singhani V, Ehsan M, Valencia S, et al.
Journal: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2026 Oct
PMID: 42808923
DOI: 10.1002/ncp.70180
Authors: Triantafyllou K, Tziatzios G, Tham TC, et al.
Journal: Endoscopy, 2026 Oct
PMID: 42480549
DOI: 10.1055/a-2898-6540
2. Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma.
Authors: Tran NH, Palmer ME, Ulrich A, et al.
Journal: The oncologist, 2026 Sep 9
PMID: 42640574
DOI: 10.1093/oncolo/oyag343
3. Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
Authors: Yen CJ, Chen MH, Chen YY, et al.
Journal: British journal of cancer, 2026 Oct
PMID: 42393461
DOI: 10.1038/s41416-026-03515-w
4. Targeting the CD31 immunometabolic axis: Precision strategies for modulating T cell activation, migration, and autophagy.
Authors: Han X, Yang F, Huang C, et al.
Journal: Pathology, research and practice, 2026 Oct
PMID: 42492206
DOI: 10.1016/j.prp.2026.156629
5. MicroRNA-122 as a regulator and biomarker of liver disease.
Authors: Ahmadova S, Wicik Z, Mucha J, et al.
Journal: Journal of molecular medicine (Berlin, Germany), 2026 Sep 19
PMID: 42760391
DOI: 10.1007/s00109-026-02718-1
6. Colorectal cancer organoid co-culture systems and their applications in drug screening.
Authors: Xu Y, Xing T, Zhang S, et al.
Journal: Chemico-biological interactions, 2026 Oct 1
PMID: 42551539
DOI: 10.1016/j.cbi.2026.112277
7. Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.
Authors: Tavaglione F, Loomba R
Journal: Cell reports. Medicine, 2026 Sep 15
PMID: 42697203
DOI: 10.1016/j.xcrm.2026.103023
8. The circadian-melatonin axis in breast cancer metastasis: molecular mechanisms, organ-specific metastatic niches, and therapeutic opportunities.
Authors: Wang CH, Chong KH, Cheng CF, et al.
Journal: Frontiers in endocrinology, 2026
PMID: 42755785
DOI: 10.3389/fendo.2026.1941609
9. Overcoming Biophysical Barriers in Melanoma Photomedicine: From Photodynamic Therapy to Smart Nanodelivery and Photoimmunotherapy.
Authors: Russano F, Dall'Olmo L, Brugnolo D, et al.
Journal: International journal of molecular sciences, 2026 Sep 13
PMID: 42794589
DOI: 10.3390/ijms27188156
10. Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Authors: Singhani V, Ehsan M, Valencia S, et al.
Journal: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition, 2026 Oct
PMID: 42808923
DOI: 10.1002/ncp.70180
